FORM 4

1. Name and Address of Reporting Person

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

2. Issuer Name and Ticker or Trading Symbol

Washington, D.C. 20549

OMB APPROVAL												
OMB Number:	3235-028											

5. Relationship of Reporting Person(s) to Issuer

37 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 Estimated average burden obligations may continue. See 0.5 hours per response: Instruction 1(b) Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Richards Christos					_ <u>Cc</u>	Coherus BioSciences, Inc. [CHRS]								(Check X	all applicable) Director			% Owner
(Last) (First) (Middle) C/O COHERUS BIOSCIENCES, INC. 201 REDWOOD SHORES PARKWAY, SUITE 200						3. Date of Earliest Transaction (Month/Day/Year) 11/12/2015									Offic below	er (give title w)		ner (specify ow)
(Street) REDWO CITY (City)	C/		94065 (Zip)		_ 4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv Line) X	idual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
		Tabl	le I - I	Non-Deriv	/ative	Sec	uritie	s Ad	cquir	ed, D	isposed c	of, or E	Benefic	ially (Owne	ed		
Date			2. Transacti Date (Month/Day		Execution Date		<i>'</i>	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			d 5) Sec Ben		ount of rities ficially ed Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	of Indirect	
									Code	v	Amount	(A) or (D)	Price		Trans	action(s) 3 and 4)		(111511.4)
Common Stock, \$0.0001 par value 11/12/201					015	5			S		3,000	D	\$27.23	309(1)		75,836	D	
Common Stock, \$0.0001 par value 11/13/2				015	5			S		7,988	D	\$27.37	762 ⁽²⁾	(67,848	D		
Common Stock, \$0.0001 par value 11/13/20				015	.5			S		4,012	D	\$27.9	29 ⁽³⁾	63,836		D		
		Та	able II								posed of, convertib				vned			
1. Title of Derivative Security (Instr. 3)	erivative ecurity nstr. 3) Conversion or Exercise Price of Derivative Security Date (Month/Day/Year) It any (Month/Day/Year) Required to the conversion of Execution Date, if any (Month/Day/Year) Required to the conversion of Execution Date, if any (Month/Day/Year) Required to the conversion of Execution Date, if any (Month/Day/Year) Required to the conversion of Execution Date, if any (Month/Day/Year)			4. Transa Code (8)	(Instr.	of Deriv Secu Acqu (A) or Dispo of (D) (Instr and 5	erivative (Month/Dispersion (In Inc.) (Month/Dispersion (In Inc.)		ration [Expiration	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe of		Deriv Secu (Inst		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form: Direct (D or Indire (I) (Instr.	Beneficial Ownership ct (Instr. 4)	

Explanation of Responses:

- 1. The transaction was executed in multiple trades in prices ranging from \$26.88 to \$27.58, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- 2. The transaction was executed in multiple trades in prices ranging from \$26.69 to \$27.66, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- 3. The transaction was executed in multiple trades in prices ranging from \$27.70 to \$28.29, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.

Remarks:

/s/ Jean Frederic Viret, as Attorney-in-Fact for Christos 11/16/2015 Richards

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.